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Introduction
The solutions to the global antimicrobial resistance crisis require a reduction in the volume of antimicrobial use to reduce selection pressure, improved infection prevention to reduce transmission, and new antimicrobial agents [1] [2] [3] [4] . The first entirely novel antimicrobial agents to reach early clinical use employ reactive oxygen species (ROS) as their mechanism of action. Surgihoney (SHRO), an engineered honey, is the first such product for topical use delivering sustained release of ROS as an entirely novel solution to controlling and eradicating bacteria [5] . Other ROS antimicrobial agents and delivery systems employing this mechanism are under development and will be available for clinical use in due course. ROS is rapidly active in vitro against all Gram-positive and Gram-negative bacteria tested [6] . ROS also has antifungal and antiviral properties. ROS prevents the formation of biofilms caused by a range of bacterial species in wounds [7] and in respiratory epithelium, and this will be discussed in greater detail in a subsequent Hot topics review.
ROS has been successfully used in infection prevention, eradication of multiresistant organisms [8] , prevention of surgical site infection [9] and intravascular line care [10] .
This antimicrobial mechanism has great potential for the control of bioburden and biofilm at many sites, thus providing an alternative to systemic antibiotics on epithelial/mucosal surfaces, for wound and cavity infection, chronic respiratory infections and possibly urinary infections.
ROS is a novel solution to controlling bacterial growth (preventing and treating) at many clinical sites and to treating localised infection. In addition, the one delivery system, Surgihoney (SHRO), currently licensed as a medical device also delivers healing properties (moist barrier, local nutrition, slough control, and possibly angioand neurogenerative properties) to wounds based on the additional properties of honey [11, 12] . It has great potential to reduce inappropriate antibiotic use, to support antimicrobial stewardship and to reduce antimicrobial resistance. It is simple to administer and can be applied to any healthcare system anywhere in the world.
Reactive oxygen species: antimicrobial mechanism and role in healing
Oxygen (O2) is the essential substrate required for high mitochondrial-driven adenosine triphosphate (ATP) yields and, in the context of wound healing, it supplies the increased amount of energy required for tissue renewal [13] . ROS also act as secondary messenger-signalling molecules. The term 'ROS' applies to molecules containing O2 but that have been reduced with added electrons to become a highly reactive radical format. Examples of ROS include superoxide anion (⋅O Gram-negative organisms tested, including those with multiple antibiotic resistance mechanisms, using techniques that included minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) determination and time-kill curves [6] .
SHRO is a modified honey that has been engineered to provide a constant level of H2O2 when applied to a wound [14] . The main mechanism appears to be constant production of H2O2, whose instability releases ROS [5] . The availability of ROS from SHRO can be enhanced by the level of the engineering process. In two enhanced SHRO prototypes, the ROS activities at 12 h were 7 and 10 times, respectively, the value for SHRO alone. There is a striking linear relationship between antimicrobial activity and the maximum output of ROS H2O2 from the three honey prototypes [5] .
Any new health technology innovation, such as SHRO, is required to satisfy satisfactory pharmacodynamics with appropriate dose-response characteristics. It needs to demonstrate satisfactory pharmacokinetics, which, as a topical agent, SHRO achieves. In clinical studies, SHRO has demonstrated satisfactory safety and tolerance as well as clinical efficacy and cost effectiveness in practice [6, [8] [9] [10] ].
Infections are a major problem in wound healing, initiated by microbial colonisation resulting in microbial overgrowth and biofilm formation. Antimicrobial-resistant organisms may be selected by injudicious use of broad-spectrum antimicrobials that are either ineffectual or toxic [14] . Antimicrobial stewardship is therefore important in wound care, and ROS therapy can contribute to this [15] .
Following a wound injury, a number of homeostatic processes are triggered [13] . 
Safety of SHRO and cytotoxicity to host cells
There are no published animal studies of SHRO toxicity or cytotoxicity. High levels of ROS have been documented to cause cellular damage to host cells, specifically through oxidative stress. Oxidative stress can result both in direct and indirect ROSmediated damage of nucleic acids, proteins and lipids, which can lead to disease states including inflammation, cancer, neurodegeneration and aging [16, 17] .
Although it is also possible that debridement of damaged and infected cells can aid in the wound healing process. Low levels of ROS produced by host cells are also increasingly recognised to play a critical role in regulating microbial colonisation, host immune responses and cellular function [18] .
A study reported at a national symposium on ROS investigated the cytotoxicity of SHRO [19] . Three SHRO prototypes (S1, S2 and S3), which display increasing production of H2O2, were used to evaluate their dose-response in host cells compared with a non-engineered Acacia honey and a no-treatment control. Study findings showed low cell death in all treatment groups when exposed to SHRO for <3 h, although some increase in cell death was always present when cells were treated for a longer time period. However, the lower concentrations of S2 and S3
showed lower cell death than the equivalent concentration in the less active S1, while maintaining a higher antibacterial activity as they have been engineered to produce a greater amount of H2O2. In addition, when using the higher concentration of SHRO (100 g/L), a shrinking of the cells occurred, which was attributed the osmolality of the honey as it was also observed with the Acacia honey with no significant difference between both types of honey, but when 10 g/L of S1, S2 and S3 were used the cells did not shrink.
It is important to remember that a certain level of cell death can be beneficial in wound healing in order to remove cells with damaged DNA and cells such as mast cells and nasal epithelial cells that can harbour intracellular stores of pathogens and so help them to evade the immune system [17, 18] . The data produced here are important as they form a guideline for dosage use in the future clinical trials as well as the usage of analogues in future therapeutic applications.
In clinical studies, ROS has been well tolerated and safe. SHRO has been used extensively as topical treatment of wounds [5, 6, [8] [9] [10] 20] . In these studies and in SHRO has been evaluated in chronic wounds in an open-label multicentre study and has shown, through its ROS activity, to reduce bacterial bioburden and biofilm and to support healing [20] . SHRO has been shown to eradicate multiresistant organisms from superficial sites and intravascular catheters [8, 10] and to prevent surgical site infection [9] . This last study was a temporal study comparing surgical site infection rates in Caesarean section wounds before and after an intervention with a single application of SHRO at wound closure. A striking 60% reduction in wound infection was recorded and, whilst this study has significant limitations, it nevertheless paves the way for future randomised controlled trials of ROS in surgical prophylaxis. ROS might work with or in some cases replace surgical antibiotic prophylaxis. 
Reactive oxygen species therapy in developing health economies
Wound management in the developing world has many challenges. Living conditions are often poor and overcrowded and the environment is hot and dusty or in the rainy season wet and muddy. Keeping skin clean and free from dirt and pathogens is difficult. It can be achieved by washing with soap and water, but in many parts of the world accessing water is difficult and soap may be too expensive. Approximately 2.5 billion people globally do not have access to an improved water supply, which is one that comes from a stand pipe or protected well or spring or rain water [25] . This water often has to be carried some distance from its source to their homes. It is heavy work as a 25 L container of water weights 25 kg and it is often undertaken by women and children. Owing to lack of easy access to water, priority is given to using it for drinking, cooking and giving it to animals rather than washing the skin. But even if water from an improved water source is used to clean skin it may not necessarily be free of pathogens and of drinkable quality [26] , so even minor wounds often become infected.
There is also the difficulty of low literacy and low health literacy levels. These, together with the distances required to access healthcare facilities, sometimes result in local healers being accessed to give advice on wound care. This, at times, results in harmful treatments being used with subsequent deterioration in the condition of the wound and of the patient.
Payment is sometimes required for health care so often the very poor will delay seeking treatment until their wound is grossly infected and very painful. Tetanus is not uncommon in children in some areas. Malnutrition and anaemia often due to malaria are other factors that delay or prevent wound healing, together with undiagnosed and untreated co-morbidities such as diabetes.
The wound cleansers used in health facilities usually consist of lotions such as Savlon TM in various dilutions or diluted bleach (NaOCI), neither of which is now used in the UK, or sterile saline that is expensive. In the developed world, drinkable quality water is generally used for cleaning wounds [27] .
Wound dressings are mainly made of gauze cut from rolls and then made into swabs by nurses. They are then autoclaved in drums, but once the drums are opened the swabs inside do not remain sterile for very long. The swabs may also loosen cotton fibres, which may provide a focal point for infection in the wounds. For exuding wounds, the gauze is covered with cotton wool padding. Autoclaved Vaseline TM gauze is placed on burns. Gauze bandages or tape is used to secure dressings.
Both gauze and Vaseline TM gauze tend to stick to the wound, causing pain and trauma on removal and also the removal of any new tissue. Pain is an issue, especially for those with burns where painkillers may not be given due to cost.
A trial of SHRO was undertaken in two hospitals in Africa (video). One was a rural hospital in Uganda and the other a town hospital in Ethiopia. The hospital staff were given supplies of the product, taught the benefits of honey in wound management, the quantities required to apply to different sized wounds and the frequency of dressing changes. This was followed by practical demonstrations and written instructions. A tablet computer was given to each hospital to anonymously record details of the patients and photographs of their wounds over a period of time on prewritten forms. Approximately 20 patients in each hospital were treated with SHRO.
The wounds included extensive burns, ulcers including diabetic ulcers, wounds caused by trauma and post-operative wounds. All of the wounds improved significantly in terms of slough, exudate and healing with less wound trauma.
Measurement of bioburden by culture was not possible due to lack of facilities. Some wounds required no oral antibiotics, thus reducing antibiotic use and making an important cost-saving. The dressings were easy to remove, resulting in less pain.
Only one patient who had surgical amputation of her arm following a road traffic accident complained of stinging on application. There were no other adverse effects.
There is a huge need in developing countries for wound products that are sterile, easy to apply, and that do not cause trauma to the wound, pain on removal or leave fibres in the wound that may be a source of infection or inflammation. Dressings also need to be antimicrobial and antifungal in order to treat infected wounds and potentially reduce the need for antibiotics and antifungals. They need to be easy to store with a long shelf-life and not be affected by high ambient temperatures. Finally, they need to be low cost. SHRO fits these criteria. The potent antimicrobial activity of SHRO [5, 6, 10] , negligible toxicity and its efficacy in reducing wound pain and exudate [20] and disrupting biofilms that delay healing [7, 20] gives SHRO considerable potential for improving wound care in the developing world. Healing promotion Large observational study [20] In vitro studies [5] [6] [7] 11, 13] Surgical prophylaxis Reduction in rates of surgical site infection Temporal observation study [9] RCTs required RCT, randomised controlled trial; MDR, multidrug-resistant.
Conclusions

